SBF2

Across TCGA pan-cancer cohorts, SBF2 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of SBF2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SBF2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SBF2 is over-expressed in tumor, although a few such as UCEC and BRCA show the opposite, repressed pattern.

LIHC, UCEC, and BRCA are the cancer types where SBF2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SBF2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	II,III,IV	+0.657	<.001	8	view →
UCEC	All	All	−0.863	<.001	6	view →
BRCA	Female	All	−0.530	<.001	6	view →
CHOL	All	All	+1.043	.002	2	view →
PAAD	Male	All	+0.360	.046	2	view →
HNSC	All	All	+0.299	.026	2	view →
LUSC	Female	III,IV	−0.415	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

SBF2–LIHC

Open the LIHC breakdown →